Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Realty Income Corp (O) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Realty Income Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.85 (market cap $4.49B), while Realty Income Corp trades at $63.48 (market cap $59.69B). The key difference: Realty Income Corp is far larger — about 13.3× ACADIA Pharmaceuticals Inc.'s market cap, and Realty Income Corp pays a 5.08% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | O | |
|---|---|---|
Market Cap | $4.49B | $59.69B |
Sector | Health | Real Estate |
52-Week High | $28.06 | $67.56 |
52-Week Low | $20.06 | $55.93 |
Enterprise Value | $3.69B | $89.49B |
Dividend Yield | — | 5.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Realty Income (O) trades at $64.01, up 0.27% with a bullish technical signal from moving averages. The REIT maintains strong fundamentals with $5.75B revenue (2025), 92.54% gross margins, and consistent monthly dividends. Recent earnings missed expectations for three consecutive quarters, but analyst consensus remains positive with a $67.86 price target. Operating cash flow grew to $4.0B in 2025, though debt-to-asset ratio increased to 39.93%.
Outlook remains stable with dividend reliability as a key strength, but elevated P/E (51.8) and recent earnings misses pose valuation concerns. Risks include rising leverage and interest rate sensitivity. Institutional sentiment leans bullish (41% buy ratings), supporting moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
